期刊文献+

肺癌患者围化疗期血清CYFRA21-1、NSE和CA125水平变化的价值探讨 被引量:3

The study on the value of the changes of serum CYFRA21-1,NSE and CA125 levels in patients with lung cancer during the perioperative period of chemotherapy
下载PDF
导出
摘要 目的:探讨肺癌患者围化疗期血清细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)和糖类抗原125(CA125)水平变化的价值。方法:选自我院于2015年12月至2017年12月期间收治的97例肺癌患者作为研究组;另选自我院于2015年12月至2017年12月期间收治的80例肺部良性病变患者作为对照组。采集患者外周静脉血,分离血清,采用电化学发光法检测CYFRA21-1、NSE和CA125含量。比较两组患者血清CYFRA21-1、NSE和CA125含量,不同临床分期化疗前后CYFRA21-1、NSE和CA125含量变化,不同疗效化疗前后CYFRA21-1、NSE和CA125含量变化。结果:研究组血清CYFRA21-1、NSE和CA125的含量高于对照组,且差异有统计学意义(P <0. 05)。I-Ⅱ期和Ⅲ-Ⅳ期患者化疗后血清CYFRA21-1、NSE和CA125的含量较化疗前明显下降(P <0. 05);Ⅲ-Ⅳ期患者化疗前和化疗后血清CYFRA21-1、NSE和CA125的含量高于同期I-Ⅱ期患者(P <0. 05)。CR+PR和SD+PD患者化疗后血清CYFRA21-1、NSE和CA125含量均较化疗前明显下降(P <0. 05); SD+PD患者化疗前和化疗后血清CYFRA21-1、NSE和CA125含量均高于同期CR+PR患者(P <0. 05)。结论:肺癌患者血清CYFRA21-1、NSE和CA125含量明显升高,且随着病情加重含量升高越明显,化疗后其含量明显下降,有助于临床的进一步研究。 Objective:To investigate the value of serum CYFRA21-1,neuron specific enolase(NSE)and carbohydrate antigen 125(CA125)level in lung cancer patients during chemotherapy.Methods:97 cases of lung cancer received chemotherapy in our hospital from December 2015 to December 2017 were selected as the research group.80 cases of benign pulmonary lesions were selected as control group from December 2015 to December 2017.The peripheral venous blood was collected.The serum was isolated and the content of CYFRA21-1,NSE and CA125 were detected by electrochemiluminescence.The contents of serum CYFRA21-1,NSE and CA125 in two groups were compared.The levels of CYFRA21-1,NSE and CA125 in different clinical stages before and after chemotherapy were compared.The contents of CYFRA21-1,NSE and CA125 were compared before and after chemotherapy.Results:The content of serum CYFRA21-1,NSE and CA125 in the research group was higher than that of the control group,and there was a statistically significant difference(P<0.05).The serum levels of CYFRA21-1,NSE and CA125 in I-ⅡandⅢ-Ⅳstage after chemotherapy were significantly lower than that before chemotherapy(P<0.05).In theⅢ-Ⅳstage,serum levels of CYFRA21-1,NSE and CA125 were higher than thatⅠ-Ⅱstage before and after chemotherapy(P<0.05).The serum levels of CYFRA21-1,NSE and CA125 in CR+PR and SD+PD after chemotherapy were significantly lower than that before chemotherapy(P<0.05).Serum levels of CYFRA21-1,NSE and CA125 in SD+PD were higher than that in CR+PR before and after chemotherapy(P<0.05).Conclusion:The levels of serum CYFRA21-1,NSE and CA125 in patients with lung cancer increased significantly,and the level of them decreased after chemotherapy.
作者 张健 邵丽华 张征宇 Zhang Jian;Shao Lihua;Zhang Zhengyu(Oncology Department,Dandong Hospital of Traditional Chinese Medicine,Liaoning Dandong 118000,China)
出处 《现代肿瘤医学》 CAS 2019年第3期403-406,共4页 Journal of Modern Oncology
关键词 肺癌 围化疗期 细胞角蛋白19片段 神经元特异性烯醇化酶 糖类抗原125 lung cancer peri-chemotherapeutic period cytokeratin-19-fragment neuron specific enolase carbohydrate antigen 125
  • 相关文献

参考文献12

二级参考文献85

  • 1李珺,王泳,张雪松,路明.肺癌患者纤维蛋白原及D-二聚体与肿瘤分期、转移的关系[J].中华临床医师杂志(电子版),2011,5(21):6457-6459. 被引量:23
  • 2梁启廉,陈小东,李建文,王三明,张英,张远起,康旭,揭育丽.胰腺癌患者血清转化生长因子-α水平检测及手术前后对比研究[J].现代肿瘤医学,2006,14(3):308-310. 被引量:4
  • 3Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
  • 4Varughese S, Jahangir KS, Simpson CE, et al. A paradigm shift in the treatment of advanced non-small cell lung cancer[J]. Am J Med Sci, 2012, 344(2): 147-50.
  • 5Siegfried JM, Gubish CT, Rothstein ME, et al. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer[J]. J Thorac Oncol, 2012, 7(3): 485-95.
  • 6Nolen BM, Brand RE, Prosser D, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a largeprospective cohort study[J]. PLoS One, 2014, 9(4): e94928.
  • 7Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer[J].Cancer Biomark, 2014, 14(4): 207-14.
  • 8Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib[J]. Anticancer Res, 2014, 34(6): 3205-10.
  • 9Moreira AL, Eng J. Personalized therapy for lung cancer[J]. Chest, 2014, 146(6): 1649-57.
  • 10Pang L, Wang J, Jiang Y, et al. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer[J]. Exp Ther Med, 2013, 6(2): 355-60.

共引文献404

同被引文献26

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部